Comments on Topical Antifungal Drugs TFM
In recent comments on the Tentative Final Monograph for OTC topical antifungals, the Nonprescription Drug Manufacturers Association asked that FDA state in the preamble to the Final Monograph "that new combinations will be considered if new data are submitted." NDMA and Schering-Plough in separate comments requested that FDA not classify "claims regarding speed of symptomatic relief and onset of fungicidal activity provided by antifungals" as Category II, but rather consider them outside the scope of the monograph. NDMA and Schering also proposed that FDA shorten the directions for use and warnings in labeling of such products.
You may also be interested in...
Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.
The UK's Optibac responds to sustainability and naturals trends with an all-in-one immunity and gut health food supplement especially designed for children.
Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.